Can the ASCO “Value Framework” work for myeloma patients?

Cancer drug costs are high. In an effort to rationalize the use of expensive drugs, the American Society of Clinical Oncology (ASCO) has proposed what they call a “Value Framework.” This framework uses a complex points system (See Fig 1. of article).

New drug data challenge the ways we treat myeloma

At the recent annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA), important data were presented on the monoclonal antibodies elotuzumab and daratumumab. The first acts against SLAMF7 and the second against CD38. These new targets on the surface of myeloma cells provide ways to attack myeloma separate from traditional chemotherapy and the immunomodulatory drugs (IMiDs) or proteasome inhibitor “novel” agents.

Myeloma immune therapy emerges as a key theme at ASCO 2015

The 2015 annual meeting of the American Society of Clinical Oncology (ASCO) is almost upon us. It is being held in Chicago from May 29th to June 2nd. This year, approximately 100 abstracts will focus on myeloma. Thus, although many fewer than at the annual meetings of the American Society of Hematology (ASH), several abstracts of importance to the myeloma community will be presented in Chicago.

Pages